IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.297
AS - Asia 7.002
EU - Europa 5.486
SA - Sud America 1.556
AF - Africa 186
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.547
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.739
SG - Singapore 2.535
CN - Cina 1.840
IT - Italia 1.696
RU - Federazione Russa 1.689
BR - Brasile 1.235
VN - Vietnam 884
HK - Hong Kong 484
BD - Bangladesh 475
GB - Regno Unito 425
CA - Canada 342
DE - Germania 322
FR - Francia 258
FI - Finlandia 235
SE - Svezia 160
IN - India 156
IE - Irlanda 142
MX - Messico 133
TR - Turchia 128
NL - Olanda 114
AR - Argentina 104
PL - Polonia 88
UA - Ucraina 87
ID - Indonesia 77
ES - Italia 66
IQ - Iraq 66
ZA - Sudafrica 66
PK - Pakistan 58
EC - Ecuador 57
AT - Austria 45
JP - Giappone 45
IL - Israele 43
CO - Colombia 40
VE - Venezuela 34
AE - Emirati Arabi Uniti 32
LT - Lituania 27
MA - Marocco 27
UZ - Uzbekistan 27
PY - Paraguay 26
CL - Cile 21
MY - Malesia 21
PE - Perù 18
SA - Arabia Saudita 18
CR - Costa Rica 16
EG - Egitto 16
CH - Svizzera 15
KE - Kenya 14
RO - Romania 14
TN - Tunisia 14
AU - Australia 13
DZ - Algeria 13
PH - Filippine 13
BE - Belgio 12
AL - Albania 11
DO - Repubblica Dominicana 11
AZ - Azerbaigian 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
GT - Guatemala 9
JM - Giamaica 9
JO - Giordania 9
NP - Nepal 9
GR - Grecia 8
HN - Honduras 8
MC - Monaco 8
SN - Senegal 8
BO - Bolivia 6
CI - Costa d'Avorio 6
HU - Ungheria 6
IR - Iran 6
KZ - Kazakistan 6
MD - Moldavia 6
OM - Oman 6
PA - Panama 6
TH - Thailandia 6
TW - Taiwan 6
TT - Trinidad e Tobago 5
AM - Armenia 4
BG - Bulgaria 4
BH - Bahrain 4
BY - Bielorussia 4
GY - Guiana 4
KR - Corea 4
PS - Palestinian Territory 4
PT - Portogallo 4
SI - Slovenia 4
SV - El Salvador 4
AO - Angola 3
BB - Barbados 3
ET - Etiopia 3
LB - Libano 3
LV - Lettonia 3
NI - Nicaragua 3
NO - Norvegia 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BT - Bhutan 2
CG - Congo 2
GD - Grenada 2
Totale 26.489
Salva come PNG Salva come JPEG
Città #
Dallas 2.454
Singapore 1.397
Ashburn 876
Chicago 871
San Jose 829
Los Angeles 663
Beijing 632
Hong Kong 469
Salt Lake City 393
Moscow 317
Ho Chi Minh City 295
Buffalo 280
Milan 261
New York 255
Tampa 206
Council Bluffs 199
Hanoi 197
Chandler 181
Santa Clara 170
Elk Grove Village 169
Rome 169
Helsinki 151
São Paulo 150
Dublin 141
Lauterbourg 126
The Dalles 124
Boardman 121
Wilmington 112
Hefei 107
Munich 102
Pisa 97
Beauharnois 89
Orem 88
Fairfield 84
San Mateo 82
Sterling 81
Florence 80
Montreal 80
Warsaw 75
London 74
Lancaster 73
Houston 71
Seattle 71
Istanbul 66
Mexico City 66
Cambridge 65
Toronto 64
Miami 63
Denver 62
Frankfurt am Main 62
Amsterdam 59
Poplar 59
Phoenix 58
Atlanta 57
Stockholm 54
Brooklyn 51
Dulles 48
Chennai 45
Lappeenranta 44
Ottawa 44
Da Nang 43
Tokyo 43
Johannesburg 42
Portsmouth 40
Rio de Janeiro 40
Nuremberg 39
Stevenage 38
Bologna 37
Boston 35
Detroit 35
Naples 35
Turku 35
Columbus 34
Manchester 34
Tel Aviv 34
Southend 33
Falls Church 32
Hangzhou 32
Jacksonville 32
Kansas City 32
Palermo 32
Belo Horizonte 31
Washington 31
Woodbridge 31
Haiphong 30
Lawrence 30
Turin 30
Figino 29
Ankara 28
Guangzhou 27
Lucca 27
Pittsburgh 26
Mumbai 25
Paris 25
Genoa 24
Guayaquil 24
Porto Alegre 24
San Francisco 24
Tashkent 24
Shanghai 23
Totale 15.699
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.845
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.706
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 732
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 619
A simple echocardiographic score to rule out cardiac amyloidosis 391
A simple echocardiographic score to rule out cardiac amyloidosis 364
[Central apneas and cardiovascular diseases] 339
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 330
Eligibility for vericiguat in a real‐world, contemporary heart failure population 304
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 301
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 301
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 296
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 269
RNA-targeting and gene editing therapies for transthyretin amyloidosis 264
Atrial amyloidosis: mechanisms and clinical manifestations 263
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 262
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 262
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 262
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 261
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 259
Valve disease in cardiac amyloidosis: an echocardiographic score 259
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 259
Disease features and management of cardiomyopathies in women 257
Biomarkers for the diagnosis and management of heart failure: New frontiers 257
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 255
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 250
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 247
Biomarkers for the diagnosis and management of heart failure 244
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 243
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 242
Cardiac magnetic resonance in patients with muscular dystrophies 241
Role of Imaging in Cardiomyopathies 239
Valvular heart disease in patients with cardiac amyloidosis 238
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 238
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 236
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 236
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 234
Cardiovascular disease and COVID-19: les liaisons dangereuses 229
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 224
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 223
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 222
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 221
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 221
Cardiac amyloidosis: Innovations in diagnosis and treatment 219
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 218
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 218
Molecular autopsy of sudden cardiac death in the genomics era 217
Tissue Characterization in Cardiac Amyloidosis 214
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 213
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 211
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 210
Cardiac Amyloidosis: How Its Epidemiology is Changing 208
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 208
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 205
Cardiovascular toxicity from therapies for light chain amyloidosis 205
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 204
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 200
PET and Cardiac Amyloidosis 200
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 200
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 199
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 197
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 196
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 195
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 194
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 193
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 192
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 192
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 186
Sex differences in transthyretin cardiac amyloidosis 184
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 184
Pathophysiology of Cardiac Amyloidosis 180
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 180
Current and emerging drug targets in heart failure treatment 179
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 176
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 175
Coronary Artery Anomalies 174
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 171
Critical Reading of cardiovascular trials with neutral or negative results 170
Obstructive sleep apnea and cardiovascular diseases 170
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 168
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 167
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 166
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 164
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 163
Use of biomarkers to diagnose and manage cardiac amyloidosis 163
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 160
Treatment of cardiac transthyretin amyloidosis: an update 159
Safety and Efficacy of Amiodarone in a Patient With COVID-19 152
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 150
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 149
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 149
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 149
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 144
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 143
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 142
Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry 134
Statin therapy in COVID-19 infection 133
The unbearable underreporting of comorbidities in heart failure clinical trials 131
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 129
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 124
Totale 25.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.362
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.175 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.628
2025/202615.832 840 2.010 2.133 2.037 1.493 1.030 1.399 760 1.081 1.087 1.069 893
2026/2027374 374 0 0 0 0 0 0 0 0 0 0 0
Totale 26.700